SRPT (STOCKS)
Sarepta Therapeutics,, Inc. Common Stock
$17.430000
-0.530000 (-2.95%)
Prev close: $17.960000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Douglas S. Ingram
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,828.54M
- Employees
- 1,372
- P/E (TTM)
- -6.02
- P/B (TTM)
- 1.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
6
Buy
16
Hold
4
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Sep 2025 (Q3)
|
$-0.01 | $-0.83 | +0.8217 | +98.80% |
|
Jun 2025 (Q2)
|
$1.89 | $0.77 | +1.1243 | +146.83% |
|
Mar 2025 (Q1)
|
$-4.60 | $-0.97 | -3.6341 | -376.24% |
|
Dec 2024 (Q4)
|
$1.50 | $1.93 | -0.4349 | -22.48% |
Financial Statements
| Revenues | $2.41B |
| Benefits Costs and Expenses | $2.67B |
| Costs And Expenses | $2.54B |
| Nonoperating Income/Loss | -$125.67M |
| Operating Expenses | $2.54B |
| Selling, General, and Administrative Expenses | $527.29M |
| Other Operating Expenses | $2.01B |
| Operating Income/Loss | -$126.52M |
| Income/Loss From Continuing Operations After Tax | -$271.51M |
| Income/Loss From Continuing Operations Before Tax | -$252.19M |
| Income Tax Expense/Benefit | $19.33M |
| Interest Expense, Operating | -$24.02M |
| Net Income/Loss | -$271.51M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$271.51M |
| Net Income/Loss Available To Common Stockholders, Basic | -$271.51M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$2.70 |
| Diluted Earnings Per Share | -$2.81 |
| Basic Average Shares | 296,010,000 |
| Diluted Average Shares | 312,525,000 |
| Assets | $3.49B |
| Current Assets | $2.72B |
| Inventory | $1.08B |
| Other Current Assets | $1.65B |
| Noncurrent Assets | $771.13M |
| Fixed Assets | $358.94M |
| Other Non-current Assets | $412.19M |
| Liabilities | $2.17B |
| Current Liabilities | $921.43M |
| Accounts Payable | $94.02M |
| Wages | $30.96M |
| Other Current Liabilities | $796.45M |
| Noncurrent Liabilities | $1.25B |
| Long-term Debt | $1.04B |
| Other Non-current Liabilities | $216.75M |
| Equity | $1.32B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.32B |
| Liabilities And Equity | $3.49B |
| Net Cash Flow From Operating Activities | -$244.64M |
| Net Cash Flow From Operating Activities, Continuing | -$244.64M |
| Net Cash Flow From Investing Activities | $737.55M |
| Net Cash Flow From Investing Activities, Continuing | $737.55M |
| Net Cash Flow From Financing Activities | -$80.15M |
| Net Cash Flow From Financing Activities, Continuing | -$80.15M |
| Net Cash Flow | $412.77M |
| Net Cash Flow, Continuing | $412.77M |
| Comprehensive Income/Loss | -$273.54M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$273.54M |
| Other Comprehensive Income/Loss | -$2.03M |